Chordomas of the craniospinal axis: Multimodality surgical, radiation and medical management strategies

Expert Review of Neurotherapeutics

Volumn 7, Issue 10, 2007, Pages 1295-1312

  Muro, Kenji ^a   Das, Sunit ^a   Raizer, Jeffrey J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemotherapy; Chordoma; Radiation; Sacral; Skull base

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; RUBITECAN; VINCRISTINE;

CANCER RADIOTHERAPY; CHORDOMA; CRANIOSPINAL AXIS CHORDOMA; DISEASE FREE SURVIVAL; HUMAN; INCIDENCE; PATHOPHYSIOLOGY; PHOTON; PREVALENCE; REVIEW; SKULL SURGERY;

ANIMALS; CHORDOMA; COMBINED MODALITY THERAPY; HUMANS; SKULL NEOPLASMS; SPINAL NEOPLASMS;

EID: 35548985445     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.10.1295     Document Type: Review

References (125)

1. Cesinaro AM, Maiorana A, Collina G, Fano RA. Extra-axial chordoma. Report of a case with immunohistochemical study. Pathologica 85, 755-760 (1993).
2. Lu CY, Chai CY, Chiang IC. Chordoma mimicking the trigeminal schwannoma: a case report. Clin. Imaging 28, 187-190 (2004).
3. DiFrancesco LM, Davanzo Castillo CA, Temple WJ. Extra-axial chordoma. Arch. Pathol. Lab. Med. 130, 1871-1874 (2006).
4. Currier BL, Papagelopoulos PJ, Krauss WE, Unni KK, Yaszemski MJ. Total en bloc spondylectomy of C5 vertebra for chordoma. Spine 32, E294-E299 (2007).
5. Kendall BE. Cranial chordomas. Br. J. Radiol. 50, 687-698 (1977).
6. Azzarelli A, Quagliuolo V, Cerasoli S et al. Chordoma: natural history and treatment results in 33 cases. Eur. J. Surg. Oncol. 37, 185-191 (1988).
7. Lanzino G, Dumont AS, Lopes MB, Laws ER Jr. Skull base chordomas: overview of disease, management options, and outcome. Neurosurg. Focus 10, E12 (2001).
8. Campbell WM, McDonald TJ, Unni KK, Laws ER Jr. Nasal and paranasal presentations of chordomas. Laryngoscope 90, 612-618 (1980).
9. Higinbotham NL, Phillips RF, Farr HW, Hustu HO. Chordoma. Thirty-five-year study at Memorial Hospital. Cancer 20, 1841-1850 (1967).
10. O'Connell JX, Renard LG, Liebsch NJ, Efird JT, Munzenrider JE, Rosenberg AE. Base of skull chordoma. A correlative study of histologic and clinical features of 62 cases. Cancer 74, 2261-2267 (1994).
11. Arnold H, Herrmann HD. Skull base chordoma with cavernous sinus involvement. Partial or radical tumour-removal? Acta Neurochir. (Wien) 83, 31-37 (1986).
12. Sekhar LN, Møller AR. Operative management of tumors involving the cavernous sinus. J. Neurosurg. 64, 879-889 (1986).
13. Lanzino G, Hirsch WL, Pomonis S, Sen CN, Sekhar LN. Cavernous sinus tumors: neuroradiologic and neurosurgical considerations on 150 operated cases. J. Neurosurg. Sci. 36, 183-196 (1992).
14. Lanzino G, Sekhar LN, Hirsch WL, Sen CN, Pomonis S, Snyderman CH. Chordomas and chondrosarcomas involving the cavernous sinus: review of surgical treatment and outcome in 31 patients. Surg. Neurol. 40, 359-371 (1993).
15. Goel A, Muzumdar DP, Nitta J. Surgery on lesions involving cavernous sinus. J. Clin. Neurosci. 8, 71-77 (2001).
16. Fleming RA, Wilson MW, Fuller CE, Fleming JC, Haik BG. Clinical and pathological features of intracranial chordoma with orbital involvement in a child. Ophthal. Plast. Reconstr. Surg. 19, 240-242 (2003).
17. al-Mefty O, Borba LA. Skull base chordomas: a management challenge. J. Neurosurg. 86, 182-189 (1997). • Thorough review of applied surgical approaches to skull base region chordomas.
18. Chandawarkar RY. Sacrococcygeal chordoma: review of 50 consecutive patients. World J. Surg. 20, 717-719 (1996).
19. Cheng EY, Ozerdemoglu RA, Transfeldt EE, Thompson RC Jr. Lumbosacral chordoma. Prognostic factors and treatment. Spine 24, 1639-1645 (1999).
20. York JE, Kaczaraj A, Abi-Said D et al. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 44, 74-79 (1999).
21. Fourney DR, Gokaslan ZL. Current management of sacral chordoma. Neurosurg. Focus 15, E9 (2003).
22. Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW. Chordomas and cartilaginous tumors at the skull base. Cancer 32, 410-420 (1973).
23. O'Neill P, Bell BA, Miller JD, Jacobson I, Guthrie W. Fifty years of experience with chordomas in southeast Scotland. Neurosurgery 16, 166-170 (1985).
24. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 12(1), 1-11 (2001).
25. Barnes L, Kapadia SB. The biology and pathology of selected skull base tumors. J. Neurooncol. 20(3), 213-240 (1994).
26. Sundaresan N, Huvos AG, Krol G, Lane JM, Brennan M. Surgical treatment of spinal chordomas. Arch. Surg. 122(12), 1479-1482 (1987).
27. Brandal P, Bjerkehagen B, Danielsen H, Heim S. Chromosome 7 abnormalities are common in chordomas. Cancer Genet. Cytogenet. 160(1), 15-21 (2005).
28. Riva P, Crosti F, Orzan F et al. Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int. J. Cancer 107(3), 493-497 (2003).
29. Klingler L, Shooks J, Fiedler PN, Marney A, Butler MG, Schwartz HS. Microsatellite instability in sacral chordoma. Eur. J. Surg. Oncol. 73(2), 100-103 (2000).
30. Kelley MJ, Korczak JF, Sheridan E, Yang X, Goldstein AM, Parry DM. Familial chordoma, a tumor of notochordal remnants, is linked to chromosome 7q33. Am. J. Hum. Genet. 69(2), 454-460 (2001).
31. Weinberger PM, Yu Z, Kowalski D et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch. Otolaryngol. Head Neck Surg. 131(8), 707-711 (2005).
32. Tamborini E, Miselli F, Negri T et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR)B, PDGFRA, and KIT receptors in chordomas. Clin. Cancer Res. 12(23), 5928-6920 (2006).
33. Mori K, Chano T, Kushima R, Hukuda S, Okabe H. Expression of E-cadherin in chordomas: diagnostic marker and possible role of tumor cell affinity. Virchows Arch. 440(2), 123-127 (2002).
34. Saad AG, Collins MH. Prognostic value of MIB-1, E-cadherin, and CD44 in pediatric chordomas. Pediatr. Dev. Pathol. 8(3), 362-368 (2005).
35. Pallini R, Maira G, Pierconti F et al. Chordoma of the skull base: predictors of tumor recurrence. J. Neurosurg. 98(4), 812-822 (2003).
36. Colli B, al-Mefty O. Chordomas of the craniocervical junction: follow-up review and prognostic factors. J. Neurosurg. 95, 933-943 (2001).
37. Crockard HA, Steel T, Plowman N et al. A multidisciplinary team approach to skull base chordomas. J. Neurosurg. 95, 175-183 (2001).
38. Sekhar LN, Pranatartiharan R, Chanda A, Wright DC. Chordomas and chondrosarcomas of the skull base: results and complications of surgical management. Neurosurg. Focus 10, E2 (2001).
39. Tzortzidis F, Elahi F, Wright D, Natarajan SK, Sekhar LN. Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 59, 230-237 (2006). • Reports the long-term follow-up results of a large cohort of patients who underwent aggressive skull base surgery for chordomas.
40. Chetty R, Levin CV, Kalan MR. Chordoma: a 20-year clinicopathologic review of the experience at Groote Schuur Hospital, Cape Town. Eur. J. Surg. Oncol. 46, 261-264 (1991).
41. Moriki T, Takahashi T, Wada M, Ueda S, Ichien M, Miyazaki E. Chondroid chordoma: fine-needle aspiration cytology with histopathological, immunohistochemical, and ultrastructural study of two cases. Diagn. Cytopathol. 21, 335-339 (1999).
42. Rosenberg AE, Bhan AK, Lee JM. Chondroid chordoma. Am. J. Clin. Pathol. 104, 484 (1995).
43. Weber AL, Liebsch NJ, Sanchez R, Sweriduk ST, Jr. Chordomas of the skull base. Radiologic and clinical evaluation. Neuroimaging Clin. N. Am. 4, 515-527 (1994).
44. Tamaki N, Nagashima T, Ehara K, Motooka Y, Barua KK. Surgical approaches and strategies for skull base chordomas. Neurosurg. Focus 10, E9 (2001).
45. al-Mefty O, Anand VK. Zygomatic approach to skull-base lesions. J. Neurosurg. 73, 668-673 (1990).
46. Babu RP, Sekhar LN, Wright DC. Extreme lateral transcondylar approach: technical improvements and lessons learned. J. Neurosurg. 81, 49-59 (1994).
47. Davis AE, Robin PE. Transpalatal approach to the petrous apex. J. Laryngol. Otol. 103, 94-96 (1989).
48. Day JD, Fukushima T, Giannotta SL. Microanatomical study of the extradural middle fossa approach to the petroclival and posterior cavernous sinus region: description of the rhomboid construct. Neurosurgery 34, 1009-1016 (1994).
49. Harsh GR, Sekhar LN. The subtemporal, transcavernous, anterior transpetrosal approach to the upper brain stem and clivus. J. Neurosurg. 77, 709-717 (1992).
50. Kawase T, Shiobara R, Toya S. Anterior transpetrosal-transtentorial approach for sphenopetroclival meningiomas: surgical method and results in 10 patients. Neurosurgery 28, 869-875 (1991).
51. Kingdom TT, Nockels RP, Kaplan MJ. Transoral-transpharyngeal approach to the craniocervical junction. Otolaryngol. Head Neck Surg. 113, 393-400 (1995).
52. Lawton MT, Daspit CP, Spetzler RF. Transpetrosal and combination approaches to skull base lesions. Clin. Neurosurg. 43, 91-112 (1996).
53. Miller CG, van Loveren HR, Keller JT, Pensak M, el-Kalliny M, Tew JM Jr. Transpetrosal approach: surgical anatomy and technique. Neurosurgery 33, 461-469 (1993).
54. Sekhar LN, Janecka IP, Jones NF. Subtemporal-infratemporal and basal subfrontal approach to extensive cranial base tumours. Acta Neurochir. (Wien) 92, 83-92 (1988).
55. Sekhar LN, Nanda A, Sen CN, Snyderman CN, Janecka IP. The extended frontal approach to tumors of the anterior, middle and posterior skull base. J. Neurosurg. 76, 198-206 (1992).
56. Sekhar LN, Pomeranz S, Sen CN. Extradural petrous bone and petroclival neoplasms. Acta Neurochir. Suppl. (Wien) 53, 183-192 (1991).
57. Sen CN, Sekhar LN. An extreme lateral approach to intradural lesions of the cervical spine and foramen magnum. Neurosurgery 27, 197-204 (1990).
58. Sen CN, Sekhar LN. The subtemporal and preauricular infratemporal approach to intradural structures ventral to the brain stem. J. Neurosurg. 73, 345-354 (1990).
59. Tummala RP, Coscarella E, Morcos JJ. Transpetrosal approaches to the posterior fossa. Neurosurg. Focus 19, E6 (2005).
60. Tzortzidis F, Bejjani G, Papadas T et al. Craniofacial osteotomies to facilitate resection of large tumours of the anterior skull base. J. Craniomaxillofac. Surg. 24, 224-229 (1996).
61. Gonzalez LF, Crawford NR, Horgan MA, Deshmukh P, Zabramski JM, Spetzler RF. Working area and angle of attack in three cranial base approaches: pterional, orbitozygomatic, and maxillary extension of the orbitozygomatic approach. Neurosurgery 50, 550-555 (2002).
62. Zabramski JM, Kiris T, Sankhla SK, Cabiol J, Spetzler RF. Orbitozygomatic craniotomy. Technical note. J. Neurosurg. 89, 336-341 (1998).
63. al-Mefty O, Borba LA, Aoki N, Angtuaco E, Pait TG. The transcondylar approach to extradural nonneoplastic lesions of the craniovertebral junction. J. Neurosurg. 84, 1-6 (1996).
64. Tedeschi H, Rhoton AL Jr. Lateral approaches to the petroclival region. Surg. Neurol. 41, 180-216 (1994).
65. Forsyth PA, Cascino TL, Shaw EG et al. Intracranial chordomas: a clinico pathological and prognostic study of 51 cases. J. Neurosurg. 78, 741-747 (1993).
66. Gay E, Sekhar LN, Rubinstein E et al. Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery 36, 887-896 (1995).
67. Sen C, Triana A. Cranial chordomas: results of radical excision. Neurosurg. Focus 10, E3 (2001).
68. Gray SW, Singhabhandhu B, Smith RA, Skandalakis JE. Sacrococcygeal chordoma: report of a case and review of the literature. Surgery 78, 573-582 (1975).
69. Ishii K, Chiba K, Watanabe M, Yabe H, Fujimura Y, Toyama Y. Local recurrence after S2-3 sacrectomy in sacral chordoma. Report of four cases. J. Neurosurg. 97, 98-101 (2002).
70. Samson IR, Springfield DS, Suit HD, Mankin HJ. Operative treatment of sacrococcygeal chordoma. A review of twenty-one cases. J. Bone Joint Surg. Am. 75, 1476-1484 (1993).
71. Yonemoto T, Tatezaki S, Takenouchi T, Ishii T, Satoh T, Moriya H. The surgical management of sacrococcygeal chordoma. Cancer 85, 878-883 (1999).
72. Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom JM. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 88, 2122-2134 (2000).
73. Fourney DR, Rhines LD, Hentschel SJ et al. En bloc resection of primary sacral tumors: classification of surgical approaches and outcome. J. Neurosurg. Spine 3, 111-122 (2005).
74. Fourney DR, Gokaslan ZL. Spinal instability and deformity due to neoplastic conditions. Neurosurg. Focus 14, E8 (2003).
75. Jackson RJ, Gokaslan ZL. Spinal-pelvic fixation in patients with lumbosacral neoplasms. J. Neurosurg. 92, 61-70 (2000).
76. Miles WK, Chang DW, Kroll SS et al. Reconstruction of large sacral defects following total sacrectomy. Plast. Reconstr. Surg. 105, 2387-2394 (2000).
77. Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH. Operative management of sacral chordoma. J. Bone Joint Surg. Am. 87, 2211-2216 (2005).
78. Osaka S, Kodoh O, Sugita H, Osaka E, Yoshida Y, Ryu J. Clinical significance of a wide excision policy for sacrococcygeal chordoma. J. Cancer Res. Clin. Oncol. 132, 213-218 (2006).
79. Baratti D, Gronchi A, Pennacchioli E et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann. Surg. Oncol. 10, 291-296 (2003).
80. Hulen CA, Temple HT, Fox WP, Sama AA, Green BA, Eismont FJ. Oncologic and functional outcome following sacrectomy for sacral chordoma. J. Bone Joint Surg. Am. 88, 1532-1539 (2006). • Honest appraisal of the morbidity associated with aggressive surgical resection of sacral chordomas.
81. Todd LT, Yaszemski MJ, Currier BL, Fuchs B, Kim CW, Sim FH. Bowel and bladder function after major sacral resection. Clin. Orthop. Relat. Res. 397, 36-39 (2002).
82. Biagini R, Ruggieri P, Mercuri M et al. Neurologic deficit after resection of the sacrum. Chir. Organi. Mov. 82, 357-372 (1997).
83. Gunterberg B, Kewenter J, Petersén I, Stener B. Anorectal function after major resections of the sacrum with bilateral or unilateral sacrifice of sacral nerves. Br. J. Surg. 63, 546-554 (1976).
84. Nakai S, Yoshizawa H, Kobayashi S, Maeda K, Okumura Y. Anorectal and bladder function after sacrifice of the sacral nerves. Spine 25, 2234-2239 (2000).
85. Wuisman P, Lieshout O, Sugihara S, van Dijk M. Total sacrectomy and reconstruction: oncologic and functional outcome. Clin. Orthop. Relat. Res. 381, 192-203 (2000).
86. Gunterberg B, Romanus B, Stener B. Pelvic strength after major amputation of the sacrum. An exerimental study. Acta Orthop. Scand. 47, 635-642 (1976).
87. Fuller DB, Bloom JG. Radiotherapy for chordoma. Int. J. Radiat. Oncol. Biol. Phys. 15(2), 331-339 (1988).
88. Romero J, Cardenes H, La Torre A et al. Chordoma: results of radiation therapy in eighteen patients. Radiother. Oncol. 29(1), 27-32 (1993).
89. Catton C, O'Sullivan B, Bell R et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother. Oncol. 41, 67-70 (1996).
90. Zorlu F, Gurkaynak M, Yildiz F, Oke K, Atahan IL. Conventional external radiotherapy in the management of clivus chordomas with overt residual disease. Neurol. Sci. 21, 203-207 (2000).
91. Debus J, Schulz-Ertner D, Schad L et al. Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int. J. Radiat. Oncol. Biol. Phys. 47(3), 591-596 (2000).
92. Muthukumar N, Kondziolka D, Lunsford LD, Flickinger JC. Stereotactic radiosurgery for chordoma and chondrosarcoma: further experiences. Int. J. Radiat. Oncol. Biol. Phys. 41(2), 387-392 (1998).
93. Chang SD, Martin DP, Lee E, Adler JR. Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for residual or recurrent cranial base and cervical chordomas. Neurosurg. Focus 10(3), E5 (2001).
94. Rhomberg W, Bohler F, Novak H, Dertinger S, Breitfellner G. A small prospective study of chordomas treated with radiotherapy and razoxane. Strahlenther. Onkol. 179(4), 249-253 (2003).
95. Romberg W, Eiter H, Bohler F, Dertinger S. Combined radiotherapy and razoxane in the treatment of chondrosarcomas and chordomas. Anticancer Res. 26, 2407-2411 (2006).
96. Sharpe HBA, Field EO, Hellmann K. The mode of action of the cytostatic agent ICRF 159. Nature 226, 524-526 (1970).
97. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther. Onkol. 175(Suppl. 2) 57-63 (1999). • Report containing the largest cohort of patients with chordomas treated with proton beam radiotherapy
98. Hug EG, Loredo LN, Slater JD et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J. Neurosurg. 91, 432-439 (1999).
99. Noel G, Habrand JL, Mammar H et al. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protontherapie D'Orsay experience. Int. J. Radiat. Oncol. Biol. Phys. 51(2), 392-398 (2001).
100. Noel G, Feuvret L, Calugaru V et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncologica 44, 700-708 (2005).
101. Debus J, Hug EB, Liebsch NJ et al. Brainstem tolerance to conformal radiotherapy of skull base tumors. Int. J. Radiat. Oncol. Biol. Phys. 39(5), 967-975 (1997).
102. Santoni R, Liebsch N, Finkelstein DM et al. Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. Int. J. Radiat. Oncol. Biol. Phys. 41(1), 59-68 (1998).
103. Urie MM, Fullerton B, Tatsuzaki H et al. A dose response analysis of injury to cranial nerves and/or nuclei following proton beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 23(1), 27-39 (1992).
104. Castro JR, Linstadt DE, Bahary JP et al. Experience in charged particle irradiation of tumors of the skull base: 1977-1992. Int. J. Radiat. Oncol. Biol. Phys. 29(4), 647-655 (1994). • This report has the oldest cohort of patients with chordomas treated with charged ion radiotherapy.
105. Schulz-Ertner D, Haberer T, Jakel O et al. Radiotherapy for chordomas and low-grade chondrosarcomas of the skull base with carbon ions. Int. J. Radiat. Oncol. Biol. Phys. 53(1), 36-42 (2002).
106. Schulz-Ertner D, Nikoghosyan A, Thilmann C et al. Resuls of carbon ion radiotherapy in 152 patients. Int. J. Radiat. Oncol. Biol. Phys. 58(2), 631-640 (2004).
107. Amendola BE, Amendola MA, Oliver E, McClatchey KD. Chordoma: role of radiation therapy. Radiology 158(3), 839-843 (1986).
108. Park L, DeLaney TF, Liebsch NJ et al. Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int. J. Radiat. Oncol. Biol. Phys. 65(5), 1514-1521 (2006).
109. Rutz HP, Weber DC, Sugahara S et al. Extracranial chordoma: outcome in patients treated with function-preserving surgery followed by spot-scanning proton beam irradiation. Int. J. Radiat. Oncol. Biol. Phys. 67(2), 512-520 (2007).
110. Schoenthaler R, Castro JR, Petti PL, Baken-Brown K, Phillips TL. Charged particle irradiation of sacral chordomas. Int. J. Radiat. Oncol. Biol. Phys. 26(2), 291-298 (1993).
111. Imai R, Kamada T, Tsuji H et al. Carbon ion radiotherapy for unresectable sacral chordomas. Clin. Cancer Res. 10, 5741-5746 (2004). • Discusses unresectable chordomas treated with carbon ion radiotherapy with excellent results.
112. McSweeney AJ, Sholl PR. Metastatic chordoma use of mechlorethamine (nitrogen mustard) in chordoma therapy. AMA Arch. Surg. 79(1), 152-155 (1959).
113. Razis DV, Tsatsaronis A, Kyriazides I, Triantafyllou D. Chordoma of the cervical spine treated with vincristine sulfate. J. Med. 5(5), 274-277 (1974).
114. Harwick RD, Miller AS. Craniocervical chordomas. Am. J. Surg. 138(4), 512-516 (1979).
115. Pouillart P, Schwarzenberg L, Amiel JL et al. Chemotherapeutic combinations of mutually potentiating drugs. 3 - Application to primary tumors of the central nervous system. Nouv. Presse Med. 4(10), 721-724 (1975).
116. Spratt JS, Martin AE, McKeown J. Sacral chordoma: a case study and review. Eur. J. Surg. Oncol. 18(1), 101-103 (1981).
117. Meis JM, Raymond Ak, Evans HL, Charles RE, Giraldo AA. "Dedifferentiated" chordoma. A clinicopathologic and immunohistochemical study of three cases. Am. J. Surg. Pathol. 11(7), 516-525 (1987).
118. Azzarelli A, Quagliuolo V, Cerasoli S et al. Chordoma: natural history and treatment results in 33 cases. Eur. J. Surg. Oncol. 37(3), 185-191 (1988).
119. Fleming GF, Heimann PS, Stephens JK et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 72(3), 714-718 (1993).
120. Scimeca PG, James-Herry AG, Black KS, Kahn E, Weinblatt ME. Chemotherapeutic treatment for malignant chordoma in children. J. Pediatr. Hematol. Oncol. 18(2), 237-240 (1996).
121. Casali PG, Messina A, Stacchiotti S et al. Imatinib mesylate in chordoma. Cancer 101(9), 2086-2097 (2004). • Rational use of a tyrosine kinase inhibitor with evidence of radiographic response.
122. Chugh R, Dunn R, Zalupski MM et al. Phase II study of 9-nitro-comptothecin in patients with advanced chordoma or soft tissue sarcoma. J. Clin. Oncol. 23(15), 3597-3607 (2005).
123. McPherson CM, Suki D, McCutcheon IE, Gokaslan ZL, Rhines LD, Mendel E. Metastatic disease from spinal chordoma: a 10-year experience. J. Neurosurg. Spine 5(4), 277-280 (2006).
124. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordomoa. Onkologie 29(12), 572-574 (2006).
125. Schonegger K, Gelpi E, Prayer D et al. Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. Anticancer Drugs 16(10), 1139-1143 (2005).